EUVIMEDOpdag EUVIMED
Crossref

Effectiveness and Safety of Ruxolitinib Cream 15 mg/g in Patients With Non‐Segmental Vitiligo: A Real‐Life Study

Mattia Cristallo iD, Ippolita Zaza, Michelina Francesca Daddato iD, Loredana Muolo, Francesco Pugliese, Alice D'Amico, Marco Casciaro iD, Sebastiano Gangemi iD, Eustachio Nettis

International Journal of Dermatology · 2026-04 · 65 (4) · 816-818

DOI: 10.1111/ijd.70049 ↗

At a glance

Journal article in International Journal of Dermatology, published online on 2025-09-01. Written by Mattia Cristallo and 8 co-authors. Institution: Department of Precision and Regenerative Medicine and Ionian Area, Regional Reference Center for Allergic and Immunological Diseases, University of B…. Cited 4 times so far (Crossref); 5 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Eustachio Nettis has a conflict of interest with Sanofi, Abbvie, Leo Pharma, Almirall, Gsk, and Astra-Zeneca. The remaining authors have no conflicts of interest that are directly relevant to the content of this article. The data that support the findings of this study are available from the corresponding author upon reasonable request.

Subjects

Author keywords

alexithymianon‐segmental vitiligoreal‐life studyruxolitinib

Authors and institutions

  • Department of Precision and Regenerative Medicine and Ionian Area, Regional Reference Center for Allergic and Immunological Diseases, University of Bari Aldo Moro, Bari, Italy.
  • Operative Unit of Allergy and Clinical Immunology, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.

ORCID profiles: Mattia Cristallo, Michelina Francesca Daddato, Marco Casciaro, Sebastiano Gangemi

Cite

APA

Cristallo, M., Zaza, I., Daddato, M. F., Muolo, L., Pugliese, F., D'Amico, A., Casciaro, M., Gangemi, S., & Nettis, E. (2026). Effectiveness and Safety of Ruxolitinib Cream 15 mg/g in Patients With Non‐Segmental Vitiligo: A Real‐Life Study. International Journal of Dermatology, 65(4), 816-818. https://doi.org/10.1111/ijd.70049

Vancouver

Cristallo M, Zaza I, Daddato MF, Muolo L, Pugliese F, D'Amico A, et al. Effectiveness and Safety of Ruxolitinib Cream 15 mg/g in Patients With Non‐Segmental Vitiligo: A Real‐Life Study. International Journal of Dermatology. 2026;65(4):816-818. doi:10.1111/ijd.70049

BibTeX
@article{Cristallo2026,
  author = {Cristallo, Mattia and Zaza, Ippolita and Daddato, Michelina Francesca and Muolo, Loredana and Pugliese, Francesco and D'Amico, Alice and Casciaro, Marco and Gangemi, Sebastiano and Nettis, Eustachio},
  title = {Effectiveness and Safety of Ruxolitinib Cream 15 mg/g in Patients With Non‐Segmental Vitiligo: A Real‐Life Study},
  journal = {International Journal of Dermatology},
  year = {2026},
  volume = {65},
  number = {4},
  pages = {816--818},
  doi = {10.1111/ijd.70049}
}
Start for free →